1,5-二甲基吡唑并[3,4-d]嘧啶-4-酮 | 5334-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 1,5-二甲基吡唑并[3,4-d]嘧啶-4-酮
• 英文名称: 1,5-dihydro-1,5-dimethyl-4H-pyrazolo<3,4-d>pyrimidin-4-one
• 英文别名: 1,5-dimethylpyrazolo<3,4-d>pyrimidin-4-one；1,5-dimethyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one；1,5-Dimethyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-on；1,5-dimethylallopurinol；4,5-Dihydro-1,5-dimethyl-1H-pyrazolo<3,4-d>pyrimidine-4-one；1,5-Dimethyl-4-oxo-4,5-dihydro-pyrazolo<3,4-d>pyrimidin；1,5-Dimethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one；1,5-dimethylpyrazolo[3,4-d]pyrimidin-4-one
• CAS: 5334-54-3
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: PVQKQWMEXZGTMR-UHFFFAOYSA-N

物化性质

• 保留指数：
  1602.5

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  50.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,5-二甲基吡唑并[3,4-d]嘧啶-4-酮 以80%的产率得到
  参考文献：
  名称：

  LEONOVA T. S.; BABUSHKINA T. A.; YASHUNSKIJ V. G., XIMIYA GETEROTSIKL. SOEDIN., 1978, HO 3, 397-402,

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氨基-1-甲基-吡唑-4-甲腈 在 氢氧化钾 作用下， 生成 1,5-二甲基吡唑并[3,4-d]嘧啶-4-酮
  参考文献：
  名称：

  Potential Purine Antagonists. VI. Synthesis of 1-Alkyl- and 1-Aryl-4-substituted Pyrazolo[3,4-d]pyrimidines^1,2

  摘要：

  DOI：

  10.1021/jo01117a010

文献信息

• Heilmittelchemische Studien in der heterocyclischen Reihe. 25. Mitteilung. Pyrazolo-pyrimidine III Paraxanthin-, Theobromin- und Theophyllin-Analoga der Pyrazolo[3,4-d]pyrimidin-Reihe
  作者：P. Schmidt、K. Eichenberger、J. Dreuey

  DOI：10.1002/hlca.19590420132

  日期：——

  The preparation of the paraxanthine, theobromine and theophylline isomers 1,5-; 2,5- and 1,7-; 2,7- and 5,7-dimethyl-4,6-dioxo-4,5,6,7-tetrahydro-pyrazolo[3,4-d]-pyrimidines is described and their structure established. A structurally specific synthesis of the caffeine and isocaffeine isomers 1,5,7- and 2,5,7-trimethyl-4,6- dioxo-4,5,6,7-tetrahydro-pyrazolo [3,4-d]pyrimidines has been realized.

  对黄嘌呤，可可碱和茶碱异构体1，5-的制备；2.5和1.7；描述了2,7-和5,7-二甲基-4,6-二氧代-4,5,6,7-四氢-吡唑并[3,4-d]-嘧啶并确定了它们的结构。咖啡因和异咖啡因异构体1,5,7-和2,5,7-三甲基-4,6-二氧代-4,5,6,7-四氢吡唑并[3,4-d]嘧啶的结构特异性合成实现。
• Nucleosides, 38 ¹⁾ <b>The Ribonucleosides of Allopurinol</b>
  作者：Frieder W. Lichtenthaler、Eckehard Cuny

  DOI：10.1002/cber.19811140505

  日期：1981.5

  Of the various conceivable ribonucleosides of allopurinol, the N-1-, N-2-, and N-5-isomers (9c-11c) as well as the 1, 5-and 2,5-bis-ribosylated derivatives 6c and 7c have been prepared via stannic chloride-induced glycosylation of bis (trimethylsilyl)allopurinol 4 with acylated ribofuranoses (5). Trimethylsilyl triflate as catalyst in addition produced the O4-ribosylated isomer 8a. – The structures

  在别嘌呤醇的各种可能的核糖核苷中，N -1-，N -2-和N -5-异构体（9c-11c）以及1、5和2,5-双核糖基化衍生物6c和7c已经通过氯化锡诱导双（三甲基甲硅烷基）alalpurinol 4与酰化的呋喃核糖核酸酶的糖基化反应制备了（5）。三氟甲磺酸三甲基甲硅烷基酯作为催化剂还产生了O 4-核糖基化的异构体8a。–从UV，1 H和13 C NMR数据确定了产品的结构。–评估了它们的黄嘌呤氧化酶抑制活性。
• Dearomative Insertion of Fluoroalkyl Carbenes into Azoles Leading to Fluoroalkyl Heterocycles with a Quaternary Center
  作者：Linxuan Li、Yongquan Ning、Hongzhu Chen、Yongyue Ning、Paramasivam Sivaguru、Peiqiu Liao、Qingwen Zhu、Yong Ji、Graham de Ruiter、Xihe Bi

  DOI：10.1002/anie.202313807

  日期：2024.1.2

  strategy was developed for the direct conversion of azoles into various heterocyclic frameworks containing fluoroalkyl-substituted quaternary centers through dearomative one-carbon insertion using fluoroalkyl N-triftosylhydrazones. The method is scalable, tolerates diverse functional groups, and is amenable to the synthesis of medicinally relevant molecules.

  开发了一种通用的骨架环扩展策略，用于通过使用氟烷基N-三甲苯基腙进行脱芳香一碳插入，将唑类直接转化为各种含有氟烷基取代的季中心的杂环骨架。该方法具有可扩展性，可耐受不同的官能团，并且适合医学相关分子的合成。
• Methods for treating hearing loss
  申请人：Sound Pharmaceuticals Incorporated.

  公开号：US20030162747A1

  公开（公告）日：2003-08-28

  In one aspect, the present invention provides otoprotectant compositions useful for ameliorating hearing loss. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic and at least one otoprotectant selected from the group consisting of a xanthine oxidase inhibitor and a glutathione or glutathione precursor. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic, at least one xanthine oxidase inhibitor, at least one glutathione or glutathione precursor. In another aspect, the present invention provides methods for ameliorating hearing loss by administering to a subject an amount of an otoprotective composition that is effective to ameliorate hearing loss.

  在一个方面，本发明提供了用于改善听力损失的耳保护剂组合物。在一些实施方案中，耳保护剂组合物包含至少一种谷胱甘肽过氧化物酶模拟物。在一些实施方案中，耳保护剂组合物包含至少一种谷胱甘肽过氧化物酶模拟物和至少一种选自由黄嘌呤氧化酶抑制剂和谷胱甘肽或谷胱甘肽前体组成的组的耳保护剂。在某些实施方案中，耳保护组合物包含至少一种谷胱甘肽过氧化物酶模拟物、至少一种黄嘌呤氧化酶抑制剂、至少一种谷胱甘肽或谷胱甘肽前体。在另一方面，本发明提供了通过向受试者施用一定量的有效改善听力损失的耳保护组合物来改善听力损失的方法。
• Methods and compositions for treating cancer
  申请人：Kil Jonathan

  公开号：US20060211745A1

  公开（公告）日：2006-09-21

  In one aspect the present invention provides methods for treating cancer in a mammal, including the step of administering to a mammal suffering from a cancer an amount of ebselen that is sufficient to inhibit the growth of the cancer. In another aspect, the present invention provides methods for enhancing the chemotherapeutic effect of a platinum-containing chemotherapeutic agent administered to a mammal suffering from cancer.

  在一个方面，本发明提供了治疗哺乳动物癌症的方法，包括向患有癌症的哺乳动物施用足以抑制癌症生长的依布硒。在另一个方面，本发明提供了增强对患有癌症的哺乳动物施用的含铂化疗剂的化疗效果的方法。